Compare Crispr Therapeutics AG (CRSP) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Transocean Ltd — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.17B), while Transocean Ltd trades at $5.85 (market cap $6.39B). The key difference: Transocean Ltd is the larger of the two by market cap, and Transocean Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | RIG | |
|---|---|---|
Market Cap | $5.17B | $6.39B |
Sector | Health | Technology |
52-Week High | $76.78 | $7.58 |
52-Week Low | $44.34 | $2.80 |
Enterprise Value | $3.59B | $11.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Transocean (RIG) trades at $5.26, up 1.94% with neutral technical signals. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses improving to -$1.7B. Recent Q2 2026 earnings beat expectations with $0.03 EPS, and the company secured a significant $1B+ contract with Equinor, boosting long-term visibility. Analyst sentiment is divided with 39% buy ratings, while institutional activity shows mixed positioning with recent large acquisitions by Elliott Investment Management.
RIG presents a turnaround opportunity with improving operational metrics and contract wins, but significant execution risks remain. The pending Valaris merger could create synergies, though current negative profitability and high debt require careful monitoring. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial losses against the company's market position and backlog growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
